Hypothesis

Aged male muscle stem cells (MuSCs) exhibit heightened transposable element (TE) expression that triggers DNA‑sensing pathways, leading to localized loss of CTCF/cohesin binding at TAD boundaries. This boundary erosion permits ectopic enhancer–promoter contacts that shift H3K27ac from myogenic loci to inflammatory and extracellular‑matrix (ECM) enhancers, thereby locking MuSCs into a non‑productive state. Reinforcing CTCF occupancy at eroded boundaries—either by overexpressing CTCF or by stabilizing cohesin with a small‑molecule modulator—will restore proper 3D genome architecture, suppress inflammatory rewiring, and rescue myogenic differentiation despite persistent epigenetic drift.

Rationale

• et al. show that geriatric MuSCs lose ~38% of TAD insulation and gain H3K27ac at distal regulatory regions, correlating with activation of inflammatory/ECM pathways while myogenic genes retain mRNA levels but lose function {1}.
• Enhancer hierarchy studies demonstrate that an upstream enhancer loss renders a downstream enhancer inaccessible even when transcription factors are abundant, indicating that TAD integrity gates regulatory cascades {2}.
• Male MuSCs display a striking sex bias in TE activation (47 vs 9 TEs) and stronger interferon signaling {1}, suggesting that TE‑derived nucleic acids could activate cytosolic DNA sensors (cGAS‑STING) that phosphorylate CTCF or disrupt cohesin loading.
• Iron supplementation reverses epigenetic drift in aged gut stem cells, proving that chromatin architecture can be therapeutically modulated {3}.
• H3K27ac HiChIP provides 1‑kb resolution from 25‑50 k cells, enabling precise mapping of loop loss/gain in rare MuSC subsets {4}.

Combining these observations, we propose that TE‑driven innate immune signaling directly destabilizes CTCF/cohesin at specific boundaries, initiating a cascade of enhancer rewiring that overrides compensatory transcription.

Testable Predictions

1. TE inhibition reduces boundary loss – Treating aged male MuSCs with a reverse transcriptase inhibitor (e.g., lamivudine) or CRISPR‑based TE knockdown will decrease γH2AX foci at CTCF sites and increase CTCF ChIP‑seq signal at eroded boundaries.
2. CTCF reinforcement rescues myogenic output – Overexpressing a CTCF‑fusion protein tethered to a dCas9 scaffold at three validated lost boundaries will restore promoter‑enhancer loops (measured by H3K27ac HiChIP), lower H3K27ac at inflammatory enhancers, and increase MyoD‑driven myotube formation in vitro.
3. Sex‑specific effect – The same CTCF rescue will have minimal impact on aged female MuSCs, which show baseline low TE activity and intact boundaries.
4. Inflammatory pathway suppression – Successful boundary restoration will lead to decreased phospho‑STAT1 and reduced expression of CXCL10, CCL2, and ECM‑remodeling genes (Mmp9, Col1a1) without altering global H3K27ac levels.

Experimental Approach

• Cell isolation – Purify MuSCs (α7‑Integrin⁺/Sca1⁻) from young (3 mo) and geriatric (24 mo) male and female mice; sort male and female cohorts separately.
• Baseline profiling – Perform ATAC‑seq, CTCF ChIP‑seq, and H3K27ac HiChIP (25 k cells per condition) to map TE expression, boundary strength, and enhancer redistribution.
• Intervention arms – (a) TE knockdown via siRNA or lamivudine treatment; (b) dCas9‑CTCF targeting to three lost boundaries; (c) combined TE knockdown + CTCF tethering.
• Readouts – Loop integrity (HiChIP), nascent RNA (EU‑seq), differentiation (MyHC immunostaining, fusion index), and inflammatory signaling (phospho‑STAT1 flow cytometry, ELISA).
• Controls – Non‑targeting dCas9, scrambled siRNA, and vehicle treatments.

Falsifiability

If TE inhibition fails to restore CTCF binding or if CTCF tethering does not improve loop formation, inflammatory repression, or myogenic differentiation despite confirmed molecular engagement, the hypothesis is refuted. Conversely, observing rescued architecture and function only in the male‑specific TE‑high context would support the mechanistic link between sex‑biased TE activity, 3D genome erosion, and age‑related stem cell decline.